Keyphrases
Visual Acuity
100%
Macular Edema
71%
Anti-vascular Endothelial Growth Factor Therapy
42%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
42%
Quality of Life Outcomes
42%
Visual Quality
42%
5-year Outcomes
28%
Treatment Type
28%
Treatment Patterns
28%
Retreatment
14%
Fundus Photography
14%
Treatment Duration
14%
Ophthalmologist
14%
Clinical Setting
14%
Quality of Life Assessment
14%
Temporal Relations
14%
Quality of Life
14%
Intraocular Pressure
14%
Return to Play
14%
Telephone
14%
Clinical Site
14%
Natural History
14%
Funduscopic Examination
14%
Treatment Development
14%
Safety Profile
14%
Number of Treatment
14%
Life Safety
14%
Bevacizumab
14%
Drug Treatment
14%
Anti-VEGF Therapy
14%
Treatment Recommendations
14%
Vision Loss
14%
Outcome Profiles
14%
Spectral Domain Optical Coherence Tomography (SD-OCT)
14%
Baseline Factors
14%
Fluorescein Angiography
14%
Aflibercept
14%
Standard of Care
14%
Medicine and Dentistry
Central Retinal Vein Occlusion
100%
Hemiretinal Vein Occlusion
80%
Vasculotropin
70%
Visual Acuity
70%
Macular Edema
50%
Morphology
40%
Quality of Life
40%
Aflibercept
10%
Retreatment
10%
Spectral Domain Optical Coherence Tomography
10%
Drug Therapy
10%
Treatment Development
10%
Bevacizumab
10%
Study Participant
10%
Quality of Life Assessment
10%
Visual Impairment
10%
Intraocular Pressure
10%
Fluorescein Angiography
10%
Fundus Photography
10%
Pharmacology, Toxicology and Pharmaceutical Science
Central Retina Vein Occlusion
100%
Hemiretinal Vein Occlusion
80%
Vasculotropin
70%
Macular Edema
50%
Visual Impairment
10%
Bevacizumab
10%
Fluorescein
10%
Aflibercept
10%